These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7654466)

  • 1. Anticalcification and antiresorption effects of bisacylphosphonates.
    Van Gelder JM; Breuer E; Ornoy A; Schlossman A; Patlas N; Golomb G
    Bone; 1995 May; 16(5):511-20. PubMed ID: 7654466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo anticalcification effects of novel bishydroxyiminophosphonates.
    Golomb G; Schlossman A; Eitan Y; Saadeh H; Van Gelder JM; Breuer E
    J Pharm Sci; 1992 Oct; 81(10):1004-7. PubMed ID: 1432609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisacylphosphonates inhibit hydroxyapatite formation and dissolution in vitro and dystrophic calcification in vivo.
    Golomb G; Schlossman A; Saadeh H; Levi M; Van Gelder JM; Breuer E
    Pharm Res; 1992 Jan; 9(1):143-8. PubMed ID: 1589400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates and tetracycline: experimental models for their evaluation in calcium-related disorders.
    Cohen H; Solomon V; Alferiev IS; Breuer E; Ornoy A; Patlas N; Eidelman N; Hägele G; Golomb G
    Pharm Res; 1998 Apr; 15(4):606-13. PubMed ID: 9587958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates as Potential Inhibitors of Calcification in Bioprosthetic Heart Valves (Review).
    Timchenko TP
    Sovrem Tekhnologii Med; 2022; 14(2):68-78. PubMed ID: 37065429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo effects of tetrakisphosphonates on bone resorption, tumor osteolysis, ectopic calcification, and macrophages.
    Van Gelder JM; Breuer E; Schlossman A; Ornoy A; Mönkkönen J; Similä J; Klenner T; Stadler H; Krempien B; Patlas N; Golomb G
    J Pharm Sci; 1997 Mar; 86(3):283-9. PubMed ID: 9050794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation and evaluation of chitosan microspheres containing bisphosphonates.
    Patashnik S; Rabinovich L; Golomb G
    J Drug Target; 1997; 4(6):371-80. PubMed ID: 9239577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption.
    Price PA; Faus SA; Williamson MK
    Arterioscler Thromb Vasc Biol; 2001 May; 21(5):817-24. PubMed ID: 11348880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental basis for the use of bisphosphonates in Paget's disease of bone.
    Fleisch H
    Clin Orthop Relat Res; 1987 Apr; (217):72-8. PubMed ID: 3549097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling the interaction of seven bisphosphonates with the hydroxyapatite(100) face.
    Chen C; Xia M; Wu L; Zhou C; Wang F
    J Mol Model; 2012 Sep; 18(9):4007-12. PubMed ID: 22453641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates: the first 40 years.
    Russell RG
    Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models.
    Azuma Y; Sato H; Oue Y; Okabe K; Ohta T; Tsuchimoto M; Kiyoki M
    Bone; 1995 Feb; 16(2):235-45. PubMed ID: 7756053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates: structure-activity relations from a clinical perspective.
    Papapoulos SE
    Medicina (B Aires); 1997; 57 Suppl 1():61-4. PubMed ID: 9567357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of action of the bisphosphonates.
    Fleisch H
    Medicina (B Aires); 1997; 57 Suppl 1():65-75. PubMed ID: 9567358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A quantitative structure-activity relationship and pharmacophore modeling investigation of aryl-X and heterocyclic bisphosphonates as bone resorption agents.
    Kotsikorou E; Oldfield E
    J Med Chem; 2003 Jul; 46(14):2932-44. PubMed ID: 12825934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The stumble-from pipe cleaner to bone builder.
    Swislocki AL; Wexler JA
    Endocr Pract; 2007; 13(2):194-7. PubMed ID: 17490936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia.
    Iwata K; Li J; Follet H; Phipps RJ; Burr DB
    Bone; 2006 Nov; 39(5):1053-1058. PubMed ID: 16807159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the trabecular rat bone mineral: effect of ovariectomy and bisphosphonate treatment.
    Bohic S; Rey C; Legrand A; Sfihi H; Rohanizadeh R; Martel C; Barbier A; Daculsi G
    Bone; 2000 Apr; 26(4):341-8. PubMed ID: 10719276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the bisphosphonate tiludronate on bone resorption, calcium balance, and bone mineral density.
    Ammann P; Rizzoli R; Caverzasio J; Shigematsu T; Slosman D; Bonjour JP
    J Bone Miner Res; 1993 Dec; 8(12):1491-8. PubMed ID: 8304051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates and atherosclerosis: why?
    Bevilacqua M; Dominguez LJ; Rosini S; Barbagallo M
    Lupus; 2005; 14(9):773-9. PubMed ID: 16218486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.